Gene · 136
Papers1,219
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 1,219
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Stromal spatial signatures of the classical adenosine pathway dictate prognosis in hepatocellular carcinoma. | Immunol Lett | 2026 | 42815694 | PubTator, text mining | PubMed |
| TRPV4-driven ATP release activates CFTR through ADORA2B and P2RY2 receptors in the airway epithelium. | iScience | 2026 | 42707181 | PubTator, text mining | PubMed |
| Increased ADORA1 expression in pancreatic islets coincides with insulin secretory defects in human type 2 diabetes. | J Biol Chem | 2026 | 42660457 | PubTator, text mining | PubMed |
| CD73 is associated with glycolysis-related metabolic features in head and neck squamous cell carcinoma. | Eur J Oral Sci | 2026 | 42605821 | PubTator, text mining | PubMed |
| Adenosine-A Regulator of Human Testicular Peritubular Cells. | Andrology | 2026 | 42444403 | PubTator, text mining | PubMed |
| Adenosine A2B Receptor Activation: A Novel Therapeutic Strategy for Accelerating Liver Recovery After Acetaminophen Overdose. | bioRxiv | 2026 | 42427683 | PubTator, text mining | PubMed |
| Clemastine alleviates cognitive dysfunction after SAH by targeting neuronal CNTN1 to regulate the ADA-adenosine pathway. | Acta Pharmacol Sin | 2026 | 42337055 | PubTator, text mining | PubMed |
| Expression of adenosine A1, A2A, A2B, and A3 receptors in ovarian cancer: their clinical potential in diagnosis and prognosis. | Mol Biol Rep | 2026 | 42234312 | PubTator, text mining | PubMed |
Integration of network toxicology, WGCNA, and explainable machine learning to decipher the toxic molecular basis underlying DEGDB plasticizer-induced clear cell renal cell carcinoma (ccRCC) progression. | Comput Biol Chem | 2026 | 42224996 | PubTator, text mining | PubMed |
| Targeting purinergic signaling and MTAP-associated metabolism in cancer: A functional immunometabolic convergence framework. | Biochem Pharmacol | 2026 | 42082122 | PubTator, text mining | PubMed |
| ADORA2B, deubiquitinated by USP14, facilitates IL-1β-induced chondrocyte apoptosis, ferroptosis and inflammation to accelerate osteoarthritis process. | Medicine (Baltimore) | 2026 | 42071882 | PubTator, text mining | PubMed |
| Histone chaperone-based stratification combined with two-sample Mendelian randomization identifies ADORA2B and SAPCD2 as prognostic biomarkers in esophageal cancer. | Front Oncol | 2026 | 42052492 | PubTator, text mining | PubMed |
| CD73high fibroblasts orchestrate keratinocyte inflammation in the psoriasis-associated epithelial immune microenvironment. | Nat Commun | 2026 | 41957361 | PubTator, text mining | PubMed |
| Integrating Transcriptomics and 3D Spheroid Models Reveals Microenvironment-Dependent Purinergic Modulation in Hepatocellular Carcinoma. | Metabolites | 2026 | 41893304 | PubTator, text mining | PubMed |
| Dysregulation of CD39/Ectonucleoside Triphosphate Diphosphohydrolase 1 Causes Urinary Bladder Dysfunction with Abnormal Smooth Muscle Contractility. | FASEB J | 2026 | 41891871 | PubTator, text mining | PubMed |
| TGF-β mediates epigenetic control of innate antiviral responses and SIV reservoir size. | Nat Immunol | 2026 | 41862649 | PubTator, text mining | PubMed |
| A Soft Matrix Microenvironment Promotes Laterally Spreading Tumors via Oxidative Phosphorylation-Dependent Cell Adhesion. | Adv Sci (Weinh) | 2026 | 41833005 | PubTator, text mining | PubMed |
| Phase Ib multicenter study of anti-TIM-3 (S095018/Sym023) in combination with anti-PD-1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer. | J Immunother Cancer | 2026 | 41825935 | PubTator, text mining | PubMed |
| The biphasic regulatory effect of adenosine A2B receptor in ischemic brain injury and its therapeutic potential. | Purinergic Signal | 2026 | 41796357 | PubTator, text mining | PubMed |
| Enhanced antitumor efficacy of combined targeting of adenosine A2B receptor and PD-1 is mediated via multiple effects on different cell populations within tumor microenvironment. | Cancer Immunol Immunother | 2026 | 41762251 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/136/papers